Elevation Oncology Inc at Cowen Health Care Conference Transcript
(technical difficulty) analyst at GI/GU oncology panel, and with us, we have six companies. I'm just going to introduce them one by one in alphabetical order. We have Daniel O'Connor from Ambrx; we have Mark Erlander from Cardiff; we have Joe Ferra from Elevation Oncology; we have Scott Koenig from MacroGenics; Joe McCann from POINT Biopharma; and Liz Barrett from UroGen. Thank you, everybody, for joining us.
Questions & Answers
In terms of the format, we're going to ask maybe two general questions to the panelists, and then we're going to go round robin with specific company-focused questions. So first question is in GI/GU, oncology includes obviously a wide range of tumor types, each of which has unique development considerations. However, there are some regulatory factors that broadly apply to all these tumors. And I'll start with Project Optimus, how are you incorporating that in your clinical development?
So maybe let's just start with, I guess, the left side of the table.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |